Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
about
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.Tocilizumab: A Review in Rheumatoid Arthritis.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases.Enterovaginal Fistula After Tofacitinib Administration.Tocilizumab in Large Vessel Vasculitis - Different Routes of Administration
P2860
Q28074148-80CA1963-D462-4CC9-B0A7-84A8DE8E269BQ37662745-BCE4F7CF-B020-4C59-B0F6-79C1A55459C1Q38685086-52E37470-4638-4CB4-ADAE-5D16B41CFCCEQ39744551-0B9CD751-5B8D-4DAC-AC2D-C79DD521DF6BQ43280791-C656FCA6-D720-4912-B5C0-AE89F0F5A5D9Q47132835-7F97ECB5-7089-4E84-99AE-467EE1280227Q52675492-A05F30E3-C3CB-4996-9436-F6D55317231FQ54477627-6609DFFB-A038-482D-AF37-6DA48A3B5E0BQ58780767-1EE3A4C8-6C27-4462-8083-3A82753DFE37
P2860
Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@ast
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@en
type
label
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@ast
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@en
prefLabel
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@ast
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@en
P2093
P2860
P1476
Risk for lower intestinal perf ...... conventional synthetic DMARDs
@en
P2093
A Strangfeld
K Rockwitz
P2860
P304
P356
10.1136/ANNRHEUMDIS-2016-209773
P407
P577
2016-07-12T00:00:00Z